Loretta Fala
About
In The Last Decade
Loretta Fala
22 papers receiving 385 citations
Peers
Comparison fields: 5 of 87
- Molecular Biology 117
- Surgery 77
- Pulmonary and Respiratory Medicine 61
- Cardiology and Cardiovascular Medicine 58
- Endocrinology, Diabetes and Metabolism 58
Countries citing papers authored by Loretta Fala
This map shows the geographic impact of Loretta Fala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loretta Fala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loretta Fala more than expected).
Fields of papers citing papers by Loretta Fala
This network shows the impact of papers produced by Loretta Fala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loretta Fala. The network helps show where Loretta Fala may publish in the future.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations | 2 |
| 2 | Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Patients with Advanced Cutaneous Squamous-Cell Carcinoma | 0 |
| 3 | Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer | 1 |
| 4 | Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma | 7 |
| 5 | Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer | 1 |
| 6 | Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia. | 24 |
| 7 | Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure. | 7 |
| 8 | Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma. | 29 |
| 9 | Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis. | 28 |
| 10 | Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure. | 16 |
| 11 | Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non-Small-Cell Lung Cancer. | 22 |
| 12 | Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes. | 6 |
| 13 | New Perspectives in the Treatment of Opioid-Induced Respiratory Depression. | 15 |
| 14 | Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis. | 47 |
| 15 | Sivextro (Tedizolid Phosphate) Approved for the Treatment of Adults with Acute Bacterial Skin and Skin-Structure Infections. | 11 |
| 16 | Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. | 19 |
| 17 | Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. | 16 |
| 18 | Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. | 16 |
| 19 | Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis. | 27 |
| 20 | Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure. | 58 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.